VYKAT™ XR (diazoxide choline) is the First and Only FDA Approved Treatment for Hyperphagia in Prader-Willi Syndrome and Represents a Transformative Therapy Expands Neurocrine's High-Growth Commercial Portfolio to Three First-in-Class Medicines Including INGREZZA® (valbenazine) and CRENESSITY® (crinecerfont)Establishes a Durable Platform for Long-Term Revenue Growth and Value Creation, Supported by Strong VYKAT XR Intellectual Property Estate Expected to Extend into the mid-2040sNeurocrine to Host Conference Call at 8:00 AM ET Today to Discuss Transaction SAN DIEGO and REDWOOD CITY, Calif., April 6, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Soleno Therapeutics, Inc. (Nasdaq: SLNO) today announced that Neurocrine has entered into a ...

HANGZHOU, China, April 3, 2026 /PRNewswire/ -- Ridgetech, Inc., a Cayman Islands exempted company (the "Company") (Nasdaq: RDGT), a wholesale distributor of pharmaceutical and other healthcare products in China, today announced that it expects to implement a 1-for-150 reverse share split on its ordinary shares ("Ordinary Shares") effective Tuesday, April 7, 2026 at 5:00 p.m. Eastern Time, with trading to begin on a split‑adjusted basis at the market open on the next trading day. Trading in the Ordinary Shares will continue on the Nasdaq Capital Market under the symbol "RDGT." The new CUSIP number for the Ordinary Shares following the reverse share ...

TORONTO, April 6, 2026 /PRNewswire/ - DeFi Technologies Inc. (the "Company" or "DeFi Technologies") (Nasdaq: DEFT) (CBOE CA: DEFI) (GR: R9B), a financial technology company bridging the gap between traditional capital markets and decentralized finance ("DeFi"), today announced it will hold a shareholder call on Tuesday, April 7, 2026, at 11:00 a.m. EST to discuss its financial performance for the three months and twelve months ended December 31, 2025.